- Home
- LESL vs IMMX Comparison
LESL vs IMMX Comparison
Compare LESL & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LESL
- IMMX
- Stock Information
- Founded
- LESL 1963
- IMMX 2014
- Country
- LESL United States
- IMMX United States
- Employees
- LESL N/A
- IMMX N/A
- Industry
- LESL Diversified Commercial Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- LESL Miscellaneous
- IMMX Health Care
- Exchange
- LESL Nasdaq
- IMMX Nasdaq
- Market Cap
- LESL 66.9M
- IMMX 61.1M
- IPO Year
- LESL 2020
- IMMX 2021
- Fundamental
- Price
- LESL $0.36
- IMMX $2.65
- Analyst Decision
- LESL Hold
- IMMX Strong Buy
- Analyst Count
- LESL 9
- IMMX 1
- Target Price
- LESL $1.71
- IMMX $7.00
- AVG Volume (30 Days)
- LESL 4.5M
- IMMX 220.7K
- Earning Date
- LESL 08-06-2025
- IMMX 08-11-2025
- Dividend Yield
- LESL N/A
- IMMX N/A
- EPS Growth
- LESL N/A
- IMMX N/A
- EPS
- LESL N/A
- IMMX N/A
- Revenue
- LESL $1,319,859,000.00
- IMMX N/A
- Revenue This Year
- LESL $1.42
- IMMX N/A
- Revenue Next Year
- LESL $2.67
- IMMX N/A
- P/E Ratio
- LESL N/A
- IMMX N/A
- Revenue Growth
- LESL N/A
- IMMX N/A
- 52 Week Low
- LESL $0.35
- IMMX $1.26
- 52 Week High
- LESL $3.63
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- LESL 38.21
- IMMX 49.64
- Support Level
- LESL $0.40
- IMMX $2.63
- Resistance Level
- LESL $0.68
- IMMX $3.20
- Average True Range (ATR)
- LESL 0.06
- IMMX 0.22
- MACD
- LESL -0.00
- IMMX -0.04
- Stochastic Oscillator
- LESL 3.20
- IMMX 3.51
About LESL Leslie's Inc.
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products across chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company offers its products and services for Residential Pool, Residential Spa, Professional Pool, and Commercial Pool consumers. Geographically, it operates only in the United States.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.